Multifaceted roles of APOE in Alzheimer disease

RJ Jackson, BT Hyman, A Serrano-Pozo - Nature Reviews Neurology, 2024 - nature.com
For the past three decades, apolipoprotein E (APOE) has been known as the single greatest
genetic modulator of sporadic Alzheimer disease (AD) risk, influencing both the average age …

Insights into the use of biomarkers in clinical trials in Alzheimer's disease

TA Pascoal, CS Aguzzoli, FZ Lussier, L Crivelli… - …, 2024 - thelancet.com
Biomarkers have been instrumental in population selection and disease monitoring in
clinical trials of recently FDA-approved drugs targeting amyloid-β to slow the progression of …

Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes

JL Guo, D Braun, GA Fitzgerald, YT Hsieh, L Rougé… - Cell, 2025 - cell.com
While apolipoprotein E (APOE) is the strongest genetic modifier for late-onset Alzheimer's
disease (LOAD), the molecular mechanisms underlying isoform-dependent risk and the …

[HTML][HTML] Modeling the progression of neuropsychiatric symptoms in Alzheimer's disease with PET-based Braak staging

AC Macedo, J Therriault, C Tissot, É Aumont… - Neurobiology of …, 2024 - Elsevier
In Alzheimer's disease (AD), neuropsychiatric symptoms (NPS) correlate with tau deposition
in the brain. Here, we investigated the association of PET-based Braak stages with NPS and …

APOE4 impact on soluble and insoluble tau pathology is mostly influenced by amyloid-beta

C Cicognola, G Salvadó, R Smith, S Palmqvist… - Brain, 2025 - academic.oup.com
The APOE4 allele is the strongest genetic risk factor for sporadic Alzheimer's disease (AD).
While APOE4 is strongly associated with amyloid-beta (Aβ), its relationship with tau …

Plasma phospho-tau217 as a predictive biomarker for Alzheimer's disease in a large south American cohort

N Pandey, Z Yang, B Cieza, D Reyes-Dumeyer… - Alzheimer's Research & …, 2025 - Springer
Abstract Background Blood-based Alzheimer's disease (AD) biomarkers have been
increasingly employed for diagnostic, prognostic, and therapeutic monitoring purposes, due …

Hippocampal atrophy over two years in relation to tau, amyloid-β and memory in older adults

E Aumont, MA Bedard, A Bussy, JF Arias, C Tissot… - Neurobiology of …, 2025 - Elsevier
In this longitudinal brain imaging study, we aimed to characterize hippocampal tau
accumulation and subfield atrophy relative to cortical amyloid-β and memory performance …

[HTML][HTML] Influence of APOE ε4 on performance of CSF biomarkers in differentiating clinical Alzheimer's disease

Y Wang, F Li, Q Qin, T Li, Q Wang, Y Li, Y Li… - The Journal of …, 2025 - Elsevier
Abstract Introduction Apolipoprotein E ε4 (APOE ε4) bring the higher risk of
Alzheimer'Disease (AD). It is essential to evaluate whether the diagnostic performances and …

Neuropathology, Neuroimaging, and Fluid Biomarkers in Alzheimer's Disease

H Colvee-Martin, JR Parra, GA Gonzalez, W Barker… - Diagnostics, 2024 - mdpi.com
An improved understanding of the pathobiology of Alzheimer's disease (AD) should lead
ultimately to an earlier and more accurate diagnosis of AD, providing the opportunity to …

[HTML][HTML] Neurogranin in Alzheimer's Disease: Roles in synaptic function, pathology, and potential as a diagnostic biomarker

R Bavaharini, CS Somala, KM Saravanan… - AIMS Molecular …, 2024 - aimspress.com
Postsynaptic protein neurogranin (Ng), which plays a role in synaptic plasticity, learning, and
memory, has been identified as the candidate biomarker of Alzheimer's disease (AD) …